Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin in Patients With Cancer Cachexia and Low BMI
jRCT2080224663Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anamorelin in cancer anorexia-cachexia syndrome (CACS), bronchial carcinoma and gastrointestinal cancer, sponsored by Ono Pharmaceutical. Started May 2019; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)bronchial carcinomagastrointestinal cancer
Beyond the preview
Go deeper on jRCT2080224663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224663.